Sun Pharma’s partner withdraws application for marketing authorization to EMA for Nidlegy

25 Jun 2025 Evaluate

Sun Pharmaceutical Industries’ partner Philogen S.p.A (Philogen) has voluntarily withdrawn the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy, a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. Philogen’s candidate Nidlegy is partnered with Sun Pharmaceutical Industries for the treatment of Skin Cancers in Europe, New Zealand and Australia.

Philogen's decision to withdraw the Marketing Authorization Application (MAA) was due to the timing of the availability of Chemistry Manufacturing and Controls (CMC) and additional clinical data to better characterize the benefit:risk profile in patients with locally advanced resectable melanoma. Provision of the CMC and clinical data were unlikely to be completed within the current allowed timeframe.

Sun Pharmaceutical Industries (Sun Pharma) is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1712.10 -7.10 (-0.41%)
29-Dec-2025 14:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.10
Dr. Reddys Lab 1265.80
Cipla 1494.75
Zydus Lifesciences 905.25
Lupin 2084.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×